# Sotagliflozin in Patients with Diabetes and Recent Wors

New England Journal of Medicine
384, 117-128
DOI: 10.1056/nejmoa2030183

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398. | 2.9 | 19 |
| 2 | Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530. | 1.4 | 52 |
| 3 | Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOISTâ€WHF in perspective. ESC Heart Failure, 2020, 7, 3261-3267. | 1.4 | 16 |
| 4 | Discovery and care innovation amidst a pandemic. European Journal of Heart Failure, 2020, 22, 2202-2204. | 2.9 | 0 |
| 5 | Solute excretion, metabolism, and cardioâ€renoprotection via two distinct mechanisms revolutionize clinical outcomes. Acta Physiologica, 2021, 232, e13589. | 1.8 | 1 |
| 6 | Sotagliflozin reduces adverse cardiovascular events. Nature Reviews Cardiology, 2021, 18, 74-74. | 6.1 | 0 |
| 7 | <scp>SOLOISTâ€WHF</scp> and updated metaâ€analysis: sodiumâ€“glucose coâ€transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. European Journal of Heart Failure, 2021, 23, 27-30. | 2.9 | 14 |
| 8 | Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVIDâ€19: Design and rationale for the DAREâ€19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896. | 2.2 | 40 |
| 9 | Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. International Journal of Heart Failure, 2021, 3, 205. | 0.9 | 4 |
| 10 | The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 2021, 42, 657-670. | 1.0 | 25 |
| 11 | Sodiumâ€“glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 17. | 2.7 | 27 |
| 12 | Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction â€“ aÂpractical approach. Postepy W Kardiologii Interwencyjnej, 2021, 17, 135-140. | 0.1 | 1 |
| 13 | Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 351-359. | 1.8 | 13 |
| 14 | Effect of sodiumâ€“glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovascular Diabetology, 2021, 20, 25. | 2.7 | 27 |
| 15 | Do we need a definition of acute heart failure with preserved ejection fraction?. Annals of Medicine, 2021, 53, 1473-1478. | 1.5 | 0 |
| 16 | Conference highlights: The 81st Annual (Virtual) conference of the American diabetes association: June 25â€“29, 2021. Journal of Diabetes and Endocrine Practice, 2021, 4, 143. | 0.2 | 0 |
| 17 | Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal, 2021, 42, 4887-4890. | 1.0 | 11 |
| 18 | Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. International Journal of Molecular Sciences, 2021, 22, 660. | 1.8 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970. | 1.0 | 6 |
| 20 | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110421. | 1.4 | 12 |
| 21 | Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110449. | 1.4 | 0 |
| 22 | Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 172, 108648. | 1.1 | 1 |
| 23 | Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702. | 2.9 | 5 |
| 24 | New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H838-H853. | 1.5 | 18 |
| 25 | Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure. Russian Journal of Cardiology, 2021, 26, 4235. | 0.4 | 1 |
| 26 | Sodiumâ€“glucose coâ€transporter 2 inhibitorsâ€”the first successful treatment for heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2021, 23, 1256-1259. | 2.9 | 2 |
| 27 | SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Failure Reviews, 2022, 27, 951-960. | 1.7 | 16 |
| 28 | Heart failure or heart success?. Cardiovascular Research, 2021, 117, e29-e34. | 1.8 | 4 |
| 30 | Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. Endocrinology and Metabolism, 2021, 36, 41-50. | 1.3 | 4 |
| 31 | SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Failure Reviews, 2022, 27, 961-980. | 1.7 | 18 |
| 32 | Diabetes Management in Patients with Heart Failure. Diabetes and Metabolism Journal, 2021, 45, 158-172. | 1.8 | 9 |
| 33 | Novel Trial Design: CHIEF-HF. Circulation: Heart Failure, 2021, 14, e007767. | 1.6 | 23 |
| 34 | Sodiumâ€“glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834. | 2.9 | 60 |
| 35 | Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1. | 0.4 | 0 |
| 36 | Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Current Opinion in Nephrology and Hypertension, 2021, 30, 361-368. | 1.0 | 3 |
| 37 | Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75. | 2.7 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Use of <scp>sodiumâ€“glucose</scp> coâ€transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022. | 2.9 | 33 |
| 39 | Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2021, 12, 664502. | 1.5 | 2 |
| 40 | eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360, 2021, 2, 1042-1047. | 0.9 | 40 |
| 41 | Association of sodiumâ€glucose cotransporterâ€2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1431-1435. | 2.2 | 12 |
| 42 | Prevention of heart failure events with sodiumâ€“glucose coâ€transporter 2 inhibitors across a spectrum of cardioâ€renalâ€metabolic risk. European Journal of Heart Failure, 2021, 23, 1002-1008. | 2.9 | 25 |
| 43 | SGLT-2 Inhibitors in HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1393-1396. | 1.2 | 4 |
| 44 | Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes and Metabolism Journal, 2021, 45, 146-157. | 1.8 | 56 |
| 45 | SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2210-2219. | 1.4 | 26 |
| 46 | Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148. | 1.2 | 30 |
| 47 | The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. European Heart Journal, 2021, 42, 1458-1459. | 1.0 | 4 |
| 48 | Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care, 2021, 44, 1236-1241. | 4.3 | 37 |
| 49 | Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. American Heart Journal, 2021, 233, 86-91. | 1.2 | 38 |
| 50 | Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T | 0.4 | 14 |
| 51 | Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585. | 0.9 | 30 |
| 52 | Medical Therapy of Heart Failure with Reduced Ejection Fractionâ€”A Call for Comparative Research. Journal of Clinical Medicine, 2021, 10, 1803. | 1.0 | 1 |
| 53 | Cardiovascular Outcomes with Sotagliflozin. New England Journal of Medicine, 2021, 384, 1470-1473. | 13.9 | 2 |
| 54 | Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review, 0, 15, . | 0.5 | 12 |
| 55 | Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 526-536. | 1.2 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 56 | A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 632-643. | 0.8 | 31 |
| 57 | CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 531-546. | 0.8 | 170 |
| 58 | Do SGLT â€2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?. Journal of Diabetes, 2021, 13, 596-600. | 0.8 | 5 |
| 59 | Clinical Adverse Events Associated with Sodiumâ€“Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2133-2145. | 1.8 | 35 |
| 60 | Cardiorenal Protection in Diabetic Kidney Disease. Endocrinology and Metabolism, 2021, 36, 256-269. | 1.3 | 10 |
| 61 | Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovascular Diabetology, 2021, 20, 78. | 2.7 | 11 |
| 62 | Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 384, 1248-1260. | 13.9 | 60 |
| 63 | Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. Advances in Therapy, 2021, 38, 2170-2200. | 1.3 | 4 |
| 64 | Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?. Circulation, 2021, 144, 4-6. | 1.6 | 24 |
| 65 | From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92. | 2.7 | 28 |
| 66 | Sodiumâ€“glucose coâ€transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. European Journal of Heart Failure, 2021, 23, 1023-1025. | 2.9 | 1 |
| 67 | Effects of sodiumâ€glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a metaâ€analysis of randomized controlled trials. Cardiovascular Diabetology, 2021, 20, 83. | 2.7 | 20 |
| 68 | Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e74-e76. | 1.4 | 8 |
| 69 | Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14. | 1.0 | 6 |
| 70 | Sodiumâ€“glucose coâ€transporter 2 inhibitors: strength of evidence for a cardioâ€renalâ€metabolic therapy. European Journal of Heart Failure, 2021, 23, 1009-1011. | 2.9 | 0 |
| 71 | SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports, 2021, 23, 59. | 1.3 | 7 |
| 72 | Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881. | 2.9 | 160 |
| 73 | Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiology, 2021, 17, 459-473. | 0.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 74 | Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circulation Research, 2021, 128, 1468-1486. | 2.0 | 63 |
| 75 | The effect of sodiumâ€glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies. Diabetic Medicine, 2021, 38, e14600. | 1.2 | 3 |
| 76 | Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. Russian Journal of Cardiology, 2021, 26, 4436. | 0.4 | 3 |
| 77 | Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546. | 1.4 | 22 |
| 78 | Letter to the Editor regarding the article â€œSGLT2 inhibitors and cardiovascular and renal outcomes: a metaâ€‘analysis and trial sequential analysisâ€. Heart Failure Reviews, 2021, , 1. | 1.7 | 0 |
| 79 | Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21. | 1.2 | 7 |
| 80 | Vulnerable Phase of Acute Heart Failure and its Association with Hospital Readmissions Reduction Program. Current Problems in Cardiology, 2022, 47, 100904. | 1.1 | 7 |
| 81 | SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Scientific Reports, 2021, 11, 10293. | 1.6 | 37 |
| 82 | Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. Diabetes Research and Clinical Practice, 2021, 175, 108796. | 1.1 | 11 |
| 83 | Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. Diabetes Therapy, 2021, 12, 2101-2113. | 1.2 | 6 |
| 84 | Rapid evidenceâ€based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 882-894. | 2.9 | 88 |
| 85 | Timely and individualized heart failure management: need for implementation into the new guidelines. Clinical Research in Cardiology, 2021, 110, 1150-1158. | 1.5 | 18 |
| 86 | Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555. | 1.3 | 4 |
| 87 | SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF. European Journal of Internal Medicine, 2021, 87, 102-103. | 1.0 | 0 |
| 88 | Mechanisms and Models in Heart Failure. Circulation Research, 2021, 128, 1435-1450. | 2.0 | 24 |
| 89 | Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. CJC Open, 2021, 3, 646-657. | 0.7 | 2 |
| 90 | Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Failure, 2021, 8, 2580-2590. | 1.4 | 18 |
| 91 | Diabetes-Related Factors and the EffectsÂof Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology, 2021, 77, 2366-2377. | 1.2 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 92 | Epicardial adipose tissue in obesity-related cardiac dysfunction. Heart, 2022, 108, 339-344. | 1.2 | 22 |
| 93 | Does Combination Therapy With SGLT2 Inhibitors and Reninâ€“Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. Frontiers in Cardiovascular Medicine, 2021, 8, 679124. | 1.1 | 5 |
| 94 | Fluid volume regulation in patients with heart failure. Lancet Diabetes and Endocrinology,the, 2021, 9, 256-257. | 5.5 | 2 |
| 95 | SGLT2 inhibitors in cardiovascular medicine. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e67-e68. | 1.4 | 20 |
| 96 | Worsening HeartÂFailure Episodes Outside a Hospital Setting in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2021, 9, 374-382. | 1.9 | 23 |
| 97 | SGLT2 inhibitors: Do we need other evidences?. European Journal of Internal Medicine, 2021, 87, 18-19. | 1.0 | 0 |
| 98 | Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences, 2021, 22, 5863. | 1.8 | 48 |
| 100 | Eligibility of outpatients with chronic heart failure for sodiumâ€“glucose coâ€transporterâ€2 inhibitors. ESC Heart Failure, 2021, 8, 2951-2958. | 1.4 | 8 |
| 101 | From Systemic Inflammation to Myocardial Fibrosis. Circulation Research, 2021, 128, 1451-1467. | 2.0 | 132 |
| 102 | Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery. Internal Medicine Journal, 2021, , . | 0.5 | 6 |
| 103 | Use of loop diuretics in chronic heart failure: do we adhere to the <scp>Hippocratian</scp> principle â€˜do no harmâ€™?. European Journal of Heart Failure, 2021, 23, 1068-1075. | 2.9 | 4 |
| 104 | Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545. | 0.3 | 47 |
| 105 | Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem. Metabolism Open, 2021, 10, 100089. | 1.4 | 6 |
| 106 | Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis. European Journal of Endocrinology, 2021, 184, 783-790. | 1.9 | 3 |
| 107 | Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225. | 2.9 | 195 |
| 109 | Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. Cardiovascular Diagnosis and Therapy, 2021, 11, 699-706. | 0.7 | 4 |
| 110 | Sodiumâ€“glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. CKJ: Clinical Kidney Journal, 2021, 14, 2463-2471. | 1.4 | 12 |
| 111 | Sodium-glucose cotransporter 2Âinhibitors: aÂpractical guide for the Dutch cardiologist based on real-world experience. Netherlands Heart Journal, 2021, 29, 490-499. | 0.3 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 112 | SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials. Kidney Medicine, 2021, 3, 732-744.e1. | 1.0 | 10 |
| 113 | Sodiumâ€“glucose cotransporter 2 inhibitorâ€induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2631-2636. | 1.4 | 6 |
| 116 | Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovascular Diabetology, 2021, 20, 105. | 2.7 | 22 |
| 117 | Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. Cardiovascular Drugs and Therapy, 2021, 35, 1077-1078. | 1.3 | 3 |
| 118 | Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1847-1855. | 0.9 | 18 |
| 119 | Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255. | 4.9 | 2 |
| 121 | The effects of antidiabetic agents on heart failure. Netherlands Heart Journal, 2022, 30, 65-75. | 0.3 | 2 |
| 122 | Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624. | 1.7 | 19 |
| 124 | Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. Diabetology International, 2022, 13, 325-329. | 0.7 | 2 |
| 125 | Decoding empagliflozinâ€™s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Scientific Reports, 2021, 11, 12025. | 1.6 | 23 |
| 126 | Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 2022, 108, 312-320. | 1.2 | 2 |
| 127 | Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. Annales De Cardiologie Et D'Angeiologie, 2022, 71, 41-52. | 0.3 | 8 |
| 128 | Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention. Current Atherosclerosis Reports, 2021, 23, 50. | 2.0 | 7 |
| 129 | HeartÂFailure and Chronic Kidney Disease Patients. Journal of the American College of Cardiology, 2021, 78, 344-347. | 1.2 | 4 |
| 130 | Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology, 2021, 26, 4534. | 0.4 | 1 |
| 131 | Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 3057-3069. | 2.0 | 11 |
| 132 | Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 691907. | 1.1 | 26 |
| 133 | Cardio-renal benefits of sodiumâ€“glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 311-321. | 1.4 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 134 | Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. American Journal of Cardiovascular Drugs, 2021, , 1. | 1.0 | 7 |
| 136 | Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. Pharmaceuticals, 2021, 14, 751. | 1.7 | 13 |
| 137 | Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255. | 2.9 | 17 |
| 138 | Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches. Rational Pharmacotherapy in Cardiology, 2021, 17, 476-483. | 0.3 | 0 |
| 139 | Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure. American Journal of Cardiology, 2021, 151, 64-69. | 0.7 | 8 |
| 141 | Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. Drugs, 2021, 81, 1365-1371. | 4.9 | 19 |
| 142 | Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failureâ€”Optimizing Therapy With the Need for Speed. JAMA Cardiology, 2021, 6, 743. | 3.0 | 125 |
| 143 | Sodiumâ€“glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 78, 501-514. | 0.8 | 9 |
| 144 | Cardiac, renal, and metabolic effects of sodiumâ€“glucose coâ€transporter 2 inhibitors: a position paper from the European Society of Cardiology adâ€hoc task force on sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275. | 2.9 | 36 |
| 145 | Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov | 0.4 | 1 |
| 146 | Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002300. | 1.2 | 12 |
| 147 | Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501. | 2.8 | 49 |
| 148 | Sodiumâ€glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Failure, 2021, 8, 4093-4118. | 1.4 | 11 |
| 149 | Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials. Medicine (United States), 2021, 100, e26561. | 0.4 | 1 |
| 150 | SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276. | 6.3 | 222 |
| 151 | Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure. Acta Diabetologica, 2021, 58, 1579-1580. | 1.2 | 5 |
| 152 | Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC Heart Failure, 2021, 8, 4346-4352. | 1.4 | 15 |
| 153 | Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. Heart Failure Reviews, 2023, 28, 733-744. | 1.7 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 154 | Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252. | 1.8 | 23 |
| 155 | Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular Diabetology, 2021, 20, 169. | 2.7 | 17 |
| 156 | Introduction to Nephrocardiology. Cardiology Clinics, 2021, 39, 295-306. | 0.9 | 4 |
| 157 | SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovascular Drugs and Therapy, 2022, 36, 1091-1108. | 1.3 | 2 |
| 158 | Vericiguat for Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 144. | 1.3 | 19 |
| 159 | Diabetes Mellitus and Heart Failure. Journal of Clinical Medicine, 2021, 10, 3682. | 1.0 | 27 |
| 160 | Prospective association of serum adipocyte fatty acidâ€binding protein with heart failure hospitalization in diabetes. ESC Heart Failure, 2021, 8, 3964-3974. | 1.4 | 2 |
| 161 | Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891. | 0.7 | 10 |
| 162 | Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia, 2021, 40, 975-983. | 0.2 | 6 |
| 163 | New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Cardiology Clinics, 2021, 39, 335-351. | 0.9 | 10 |
| 164 | Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. Cardiology Research, 2021, 12, 210-218. | 0.5 | 7 |
| 165 | Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072. | 2.0 | 32 |
| 166 | Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605. | 1.2 | 3 |
| 167 | Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2021, 10, 3540. | 1.0 | 6 |
| 168 | ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195. | 0.0 | 5 |
| 169 | Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. Diabetes, Obesity and Metabolism, 2021, 23, 2632-2642. | 2.2 | 30 |
| 170 | Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage. European Heart Journal, 2021, 42, 4961-4963. | 1.0 | 6 |
| 171 | Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294. | 1.6 | 195 |

| # | Article | IF | Citations |
|---|---|---|---|
| 172 | Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895. | 0.7 | 14 |
| 173 | New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure, 2022, 28, 316-329. | 0.7 | 1 |
| 174 | Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738. | 1.0 | 125 |
| 175 | Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). American Journal of Cardiology, 2021, 158, 59-65. | 0.7 | 1 |
| 176 | Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461. | 13.9 | 2,143 |
| 177 | A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs, 2021, 81, 1491-1511. | 4.9 | 18 |
| 178 | SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction â€" A Win against a Formidable Foe. New England Journal of Medicine, 2021, 385, 1522-1524. | 13.9 | 14 |
| 179 | Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 90-102. | 0.4 | 3 |
| 180 | Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, 2022, 73, 321-337. | 5.0 | 52 |
| 182 | Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035. | 1.1 | 9 |
| 183 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726. | 1.0 | 5,558 |
| 184 | Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports, 2021, 3, 440-448. | 0.4 | 18 |
| 185 | Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. European Journal of Internal Medicine, 2021, 90, 10-15. | 1.0 | 6 |
| 186 | The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2021, 2021, 1-11. | 0.5 | 22 |
| 187 | Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 2021, 9, 1356. | 1.4 | 45 |
| 188 | Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108057. | 1.2 | 1 |
| 189 | Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. Cardiology, 2021, , . | 0.6 | 2 |
| 190 | The sodiumâ€"glucose coâ€transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. European Journal of Heart Failure, 2021, 23, 1673-1676. | 2.9 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 191 | Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World Journal of Cardiology, 2021, 13, 464-471. | 0.5 | 3 |
| 192 | Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112. | 0.7 | 15 |
| 194 | A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2021, 134, 1076-1084. | 0.6 | 3 |
| 195 | Sodiumâ€Glucose Coâ€Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e022222. | 1.6 | 38 |
| 196 | Sotagliflozin for patients with type <scp>2</scp> diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114. | 2.2 | 19 |
| 197 | Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload. Frontiers in Physiology, 2021, 12, 738594. | 1.3 | 11 |
| 198 | Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. Drugs - Real World Outcomes, 2022, 9, 53-62. | 0.7 | 5 |
| 199 | The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors. Journal of Diabetes and Its Complications, 2021, 35, 108052. | 1.2 | 7 |
| 200 | Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030. | 0.7 | 0 |
| 201 | Heart failure with preserved ejection fraction: a stepchild no more!. European Heart Journal, 2021, 42, 3900-3901. | 1.0 | 13 |
| 202 | Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. Journal of Clinical Medicine, 2021, 10, 4409. | 1.0 | 5 |
| 203 | Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. Journal of Clinical Medicine, 2021, 10, 4325. | 1.0 | 3 |
| 204 | Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual Review of Pharmacology and Toxicology, 2022, 62, 109-120. | 4.2 | 6 |
| 205 | Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs â€“ A systematic review. Current Diabetes Reviews, 2021, 17, . | 0.6 | 0 |
| 206 | 2021 Consensus Pathway of the TaiwanÂSociety of Cardiology on NovelÂTherapyÂfor Type 2 Diabetes. JACC Asia, 2021, 1, 129-146. | 0.5 | 1 |
| 207 | JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444. | 0.7 | 60 |
| 208 | Effects of SGLT2 Inhibitors beyond Glycemic Controlâ€"Focus on Myocardial SGLT1. International Journal of Molecular Sciences, 2021, 22, 9852. | 1.8 | 9 |
| 209 | Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116. | 6.1 | 156 |

| # | Article | IF | Citations |
|---|---|---|---|
| 210 | Sodiumâ€Glucose Cotransporter 2 Inhibitors, Allâ€Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Metaâ€Analysis and Metaâ€Regression. Journal of the American Heart Association, 2021, 10, e019918. | 1.6 | 8 |
| 212 | JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291. | 0.7 | 80 |
| 213 | Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology, 2021, 338, 248-257. | 0.8 | 1 |
| 214 | Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 4497. | 1.0 | 10 |
| 215 | Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541. | 2.0 | 52 |
| 216 | Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?. Cardiovascular Drugs and Therapy, 2023, 37, 315-321. | 1.3 | 3 |
| 217 | The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. British Journal of Diabetes, 0, , . | 0.1 | 1 |
| 218 | Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 2022, 111, 428-439. | 1.5 | 22 |
| 219 | The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia, 2021, 64, 2676-2686. | 2.9 | 44 |
| 220 | SGLT2 Inhibitors and Their Mode of Action in Heart Failureâ€”Has the Mystery Been Unravelled?. Current Heart Failure Reports, 2021, 18, 315-328. | 1.3 | 43 |
| 221 | Congestion in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 575-586. | 1.0 | 13 |
| 222 | Improving Quality of Life in Heart Failure. Current Cardiology Reports, 2021, 23, 159. | 1.3 | 22 |
| 223 | Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. Medicine (United States), 2021, 100, e27362. | 0.4 | 7 |
| 224 | Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?. European Journal of Pharmacology, 2021, 908, 174378. | 1.7 | 3 |
| 225 | Les nouvelles thÃ©rapeutiques du diabÃ¨te. La Presse MÃ©dicale Formation, 2021, 2, 574-574. | 0.1 | 0 |
| 226 | Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630. | 1.4 | 3 |
| 227 | Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis. Annals of Medicine and Surgery, 2021, 70, 102796. | 0.5 | 1 |
| 228 | Disease-modifier Drugs in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 561-573. | 1.0 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 229 | Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102282. | 1.8 | 1 |
| 230 | A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. Cardiology Research, 2021, 12, 60-66. | 0.5 | 17 |
| 231 | Cardioprotection with Yet Another SGLT2 Inhibitor â€" An Embarrassment of Riches. New England Journal of Medicine, 2021, 384, 179-181. | 13.9 | 4 |
| 232 | Heart failure drug treatment: the fantastic four. European Heart Journal, 2021, 42, 681-683. | 1.0 | 131 |
| 233 | Sodiumâ€"glucose Cotransporter 2 Inhibitorsâ€™ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International, 2021, 15, 42. | 0.4 | 0 |
| 234 | Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. Current Atherosclerosis Reports, 2021, 23, 4. | 2.0 | 5 |
| 235 | Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment. Korean Circulation Journal, 2021, 51, 399. | 0.7 | 9 |
| 236 | Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and metaâ€analysis. ESC Heart Failure, 2020, 7, 3298-3309. | 1.4 | 76 |
| 237 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020. | 1.0 | 71 |
| 238 | SGLT2 inhibitors: the statins of the 21st century. European Heart Journal, 2022, 43, 1029-1030. | 1.0 | 45 |
| 239 | Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918. | 1.5 | 42 |
| 240 | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40. | 0.7 | 9 |
| 241 | Intersection Between Diabetes and Heart Failure: Is SGLT2i the â€œOne Stone for Two Birdsâ€•Approach?. Current Cardiology Reports, 2021, 23, 171. | 1.3 | 2 |
| 242 | The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699. | 1.8 | 7 |
| 243 | Effects of an outpatient intervention comprising nurseâ€led nonâ€invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577. | 2.9 | 23 |
| 244 | Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527. | 1.4 | 46 |
| 245 | Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200. | 2.7 | 10 |
| 246 | Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 383-390. | 1.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 247 | Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Failure Reviews, 2023, 28, 709-721. | 1.7 | 14 |
| 248 | Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 664533. | 1.5 | 6 |
| 249 | Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Diseaseâ€"From Bench to Bedside. Frontiers in Physiology, 2021, 12, 755060. | 1.3 | 13 |
| 250 | Benefits and harms of sodiumâ€glucose coâ€transporterâ€2 inhibitors (SGLT2â€) and reninâ€"angiotensinâ€"aldosterone system inhibitors (RAASâ€) versus SGLT2â€s alone in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Endocrinology, Diabetes and Metabolism, 2022, 5, e00303. | 1.0 | 12 |
| 251 | Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537. | 1.2 | 25 |
| 252 | Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650. | 1.5 | 28 |
| 253 | Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 778284. | 1.1 | 2 |
| 254 | Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163. | 3.2 | 33 |
| 255 | Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783. | 1.9 | 32 |
| 256 | SelecciÃ³n de lo mejor del aÃ±o 2018 en riesgo vascular y rehabilitaciÃ³n cardiaca. REC: CardioClinics, 2019, 54, 44-50. | 0.1 | 0 |
| 257 | Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2021, , . | 0.7 | 0 |
| 258 | The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960. | 15.2 | 299 |
| 260 | Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. Journal of the American Heart Association, 2021, 10, e022667. | 1.6 | 6 |
| 261 | The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?. Expert Opinion on Pharmacotherapy, 2021, , 1-10. | 0.9 | 1 |
| 262 | Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695. | 1.7 | 3 |
| 263 | New evidence from the scientific sessions 2020 of the American Heart Association. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e1-e1. | 1.4 | 0 |
| 264 | Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 29, e227-e229. | 0.8 | 18 |
| 265 | â€˜Time is prognosisâ€™ in heart failure: timeâ€toâ€treatment initiation as a modifiable risk factor. ESC Heart Failure, 2021, 8, 4444-4453. | 1.4 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 266 | Cardiovascular benefits beyond urinary glucose excretion: <scp>A hypothesis generated from two metaâ€analyses</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 550-554. | 2.2 | 3 |
| 267 | EMPEROR-Preserved: A promise fulfilled. Cell Metabolism, 2021, 33, 2099-2103. | 7.2 | 8 |
| 268 | The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2022, 36, 561-567. | 1.3 | 16 |
| 269 | Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218. | 2.7 | 38 |
| 270 | The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge. Postgraduate Medicine, 2022, 134, 11-13. | 0.9 | 2 |
| 271 | Effectiveness and safety of empagliflozin in routine care patients: Results from the <scp>EMPagliflozin compaRative effectIveness</scp> and <scp>SafEty</scp> (<scp>EMPRISE</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 442-454. | 2.2 | 29 |
| 272 | In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors forÂHeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012. | 1.2 | 48 |
| 273 | HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2013-2016. | 1.2 | 1 |
| 274 | SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. Cleveland Clinic Journal of Medicine, 2021, 88, 601-606. | 0.6 | 2 |
| 275 | Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2021, 12, 752370. | 1.3 | 12 |
| 276 | The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. Cureus, 2021, 13, e19379. | 0.2 | 1 |
| 277 | Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690. | 1.1 | 3 |
| 278 | Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230. | 2.2 | 17 |
| 279 | The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. Journal of Personalized Medicine, 2021, 11, 1249. | 1.1 | 7 |
| 280 | Crosstalk between Sodiumâ€“Glucose Cotransporter Inhibitors and Sodiumâ€“Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. International Journal of Molecular Sciences, 2021, 22, 12677. | 1.8 | 6 |
| 281 | Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, 70, 862-871. | 1.3 | 10 |
| 282 | The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e18. | 1.2 | 22 |
| 283 | Relationship of Nonalcoholic Fatty Liver Disease and HeartÂFailure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 918-932. | 1.9 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 284 | Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 2021, 26, 7213. | 1.7 | 79 |
| 285 | SGLT-2 inhibitors as cardio-renal protective agents. Metabolism: Clinical and Experimental, 2022, 127, 154937. | 1.5 | 20 |
| 286 | Sodiumâ€“Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials. American Journal of Therapeutics, 2022, 29, e199-e204. | 0.5 | 6 |
| 287 | Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Research and Clinical Practice, 2021, 40, 555-565. | 0.9 | 8 |
| 288 | Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology, 2021, 26, 4699. | 0.4 | 1 |
| 289 | A Natural Language Processingâ€“Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Network Open, 2021, 4, e2135152. | 2.8 | 21 |
| 290 | The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors. Expert Opinion on Pharmacotherapy, 2022, 23, 321-325. | 0.9 | 7 |
| 291 | Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563. | 0.7 | 4 |
| 292 | Cardiovascular benefit of SGLT2 inhibitors. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 142-155. | 2.7 | 6 |
| 293 | Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16. | 1.1 | 4 |
| 294 | Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007. | 2.9 | 22 |
| 295 | Efficacy of Dapagliflozin in Black Versus White Patients With HeartÂFailure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64. | 1.9 | 10 |
| 296 | Glucagon-like peptide-1 receptor agonists and sodiumâ€glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine, 2022, 96, 26-33. | 1.0 | 7 |
| 298 | Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, . | 0.8 | 1 |
| 299 | Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Failure Reviews, 2023, 28, 667-681. | 1.7 | 14 |
| 300 | Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120. | 0.7 | 2 |
| 301 | Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. Frontiers in Endocrinology, 2021, 12, 743807. | 1.5 | 7 |
| 302 | Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. European Journal of Clinical Pharmacology, 2021, , 1. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 303 | Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. European Endocrinology, 2021, 17, 92. | 0.8 | 1 |
| 304 | Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease. JAMA Network Open, 2022, 5, e2142078. | 2.8 | 31 |
| 305 | The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376. | 1.0 | 13 |
| 306 | Mitochondrial dysfunction and mitochondrial therapies in heart failure. Pharmacological Research, 2022, 175, 106038. | 3.1 | 35 |
| 307 | Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges. Pharmacological Research, 2022, 176, 106049. | 3.1 | 7 |
| 308 | Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71. | 0.9 | 1 |
| 309 | Diuretics and Clinical Management of Congestion in Heart Failure: A Review. , 2021, 1, 55-62. | | 1 |
| 310 | Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fractionâ€"A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690. | 1.1 | 25 |
| 311 | Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | | 2 |
| 312 | Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350. | 1.2 | 81 |
| 313 | Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. International Journal of Heart Failure, 2022, 4, 75. | 0.9 | 10 |
| 314 | Comparative effectiveness of cardiovascular, renal and safety outcomes of secondâ€line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network metaâ€analysis of randomised controlled trials. Diabetic Medicine, 2022, 39, e14780. | 1.2 | 13 |
| 315 | SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567. | 1.4 | 20 |
| 316 | Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 787810. | 1.1 | 6 |
| 317 | SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1. | 1.1 | 25 |
| 318 | SelecciÃ³n de lo mejor del aÃ±o 2021 en insuficiencia cardiaca. REC: CardioClinics, 2022, 57, S71-S77. | 0.1 | 0 |
| 319 | Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250. | 1.2 | 11 |
| 320 | Sodiumâ€"glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441. | 2.9 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 321 | Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. Cureus, 2022, 14, e21768. | 0.2 | 1 |
| 322 | Ejection fraction in heart failure: just become Emperor's new clothes?. European Journal of Heart Failure, 2022, 24, 351-352. | 2.9 | 3 |
| 323 | The role of SGLT2 inhibitors in heart failure. , 0, 1, 2. | | 0 |
| 324 | Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. Heart Failure Reviews, 2022, , 1. | 1.7 | 4 |
| 325 | The year in cardiovascular medicine 2021: diabetes and metabolic disorders. European Heart Journal, 2022, 43, 263-270. | 1.0 | 7 |
| 326 | SGLT2 Inhibitors and Their Antiarrhythmic Properties. International Journal of Molecular Sciences, 2022, 23, 1678. | 1.8 | 24 |
| 327 | Robustness of outcomes in trials evaluating sodiumâ€“glucose coâ€transporter 2 inhibitors for heart failure. ESC Heart Failure, 2022, , . | 1.4 | 4 |
| 328 | Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. PLoS ONE, 2022, 17, e0261986. | 1.1 | 15 |
| 329 | Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040. | 1.6 | 193 |
| 330 | Response to the Letter on â€œThe Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitusâ€• Cardiovascular Drugs and Therapy, 2022, , 1. | 1.3 | 0 |
| 331 | Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076. | 2.9 | 28 |
| 332 | SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. International Journal of Cardiology, 2022, 351, 66-70. | 0.8 | 9 |
| 333 | Letter to the Editor Regarding â€œThe Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitusâ€• Cardiovascular Drugs and Therapy, 2022, , 1. | 1.3 | 0 |
| 334 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131. | 2.9 | 820 |
| 335 | Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports, 2022, 22, 39-52. | 1.7 | 55 |
| 336 | Sodiumâ€glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a metaâ€analysis. ESC Heart Failure, 2022, 9, 942-946. | 1.4 | 23 |
| 337 | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101. | 1.2 | 23 |
| 338 | Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444. | 1.2 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 339 | Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405. | 4.9 | 7 |
| 340 | Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective. International Journal of Cardiology, 2022, 349, 96-98. | 0.8 | 1 |
| 341 | Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. Clinical Drug Investigation, 2022, 42, 113-125. | 1.1 | 2 |
| 342 | New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. Advances in Medical Sciences, 2022, 67, 95-102. | 0.9 | 3 |
| 343 | Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438. | 1.2 | 5 |
| 344 | Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , . | 1.7 | 0 |
| 345 | Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift. Expert Review of Cardiovascular Therapy, 2022, , 1-4. | 0.6 | 3 |
| 346 | Four-Drug Therapy For Heart Failure with Reduced LV Ejection Fraction - Here and Now. Journal of Cardiac Failure, 2022, , . | 0.7 | 0 |
| 347 | SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Drugs and Aging, 2022, 39, 185-190. | 1.3 | 4 |
| 348 | A promise unfulfilled: the use of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction. European Journal of Heart Failure, 2022, 24, 548-550. | 2.9 | 1 |
| 349 | Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 2022, 18, 294-306. | 4.1 | 64 |
| 350 | Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care, 2022, 45, 965-974. | 4.3 | 13 |
| 351 | Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2022, 21, 20. | 2.7 | 36 |
| 352 | Nueva guÃa de insuficiencia cardiaca de la HFA-ESC 2021. Un enfoque prÃ¡ctico e integral. Revista Espanola De Cardiologia, 2022, , . | 0.6 | 1 |
| 353 | Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424. | 1.0 | 144 |
| 354 | 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S144-S174. | 4.3 | 282 |
| 355 | Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173. | 0.7 | 9 |
| 356 | Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities. Handbook of Experimental Pharmacology, 2022, , 269-307. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 357 | New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?. Journal of Cardiology, 2023, 81, 26-32. | 0.8 | 3 |
| 358 | Genetic variation in sodium glucose coâ€transporter 1 and cardiac structure and function at middle age. ESC Heart Failure, 2022, 9, 1496-1501. | 1.4 | 1 |
| 359 | Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 26-37. | 1.3 | 20 |
| 360 | Growing role of SGLT2i in heart failure: evidence from clinical trials. Expert Review of Clinical Pharmacology, 2022, 15, 147-159. | 1.3 | 8 |
| 361 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Frontiers in Pharmacology, 2022, 13, 800490. | 1.6 | 21 |
| 362 | 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244. | 0.9 | 15 |
| 363 | Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiology and Angiology, 2022, , . | 0.4 | 5 |
| 364 | The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 2022, 28, 809-813. | 15.2 | 107 |
| 365 | Review of non-insulin antidiabetic pharmacotherapy in patients with heart failure diabetes mellitus in the Czech Republic in 2018. Cor Et Vasa, 2022, 64, 20-24. | 0.1 | 1 |
| 366 | The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular Diabetology, 2022, 21, 34. | 2.7 | 10 |
| 367 | Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. Current Cardiology Reports, 2022, 24, 567-576. | 1.3 | 2 |
| 368 | Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, . | 0.4 | 6 |
| 369 | Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604. | 0.8 | 1 |
| 370 | Response of Growth Hormones and Cortisol to One Session of Moderate-Intensity Endurance Exercise in Patients with Type 2 Diabetes: A Quasi-experimental Study. Medical Journal of the Islamic Republic of Iran, 0, , . | 0.9 | 0 |
| 371 | Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 2336. | 1.8 | 4 |
| 372 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574. | 15.2 | 341 |
| 373 | An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 3651. | 1.8 | 67 |
| 374 | New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach. Revista Espanola De Cardiologia (English Ed ), 2022, 75, 548-548. | 0.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 375 | SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failureâ€"A Concise Review. Journal of Clinical Medicine, 2022, 11, 1470. | 1.0 | 16 |
| 376 | Preventing allâ€cause hospitalizations in type 2 diabetes with sodiumâ€glucose cotransporterâ€2 inhibitors and <scp>glucagonâ€like peptide</scp>â€1 receptor agonists: A narrative review and proposed clinical approach. Diabetes, Obesity and Metabolism, 2022, 24, 969-982. | 2.2 | 5 |
| 377 | Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. Expert Review of Cardiovascular Therapy, 2022, 20, 223-232. | 0.6 | 4 |
| 378 | Drugâ€"Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Safety, 2022, 45, 287-295. | 1.4 | 7 |
| 379 | Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712. | 1.6 | 57 |
| 380 | Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovascular Diabetology, 2022, 21, 47. | 2.7 | 49 |
| 381 | Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077. | 0.7 | 23 |
| 382 | Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197. | 1.9 | 75 |
| 383 | A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?. Current Cardiology Reports, 2022, , 1. | 1.3 | 2 |
| 384 | Prevalence and Prognostic Relevance of Isolated Tubular Dysfunction in Patients With Acute Heart Failure. Circulation Journal, 2022, 86, 709-714. | 0.7 | 3 |
| 385 | Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10. | 1.2 | 0 |
| 386 | Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus. UkraÃ¯nsÌkij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2022, 7, 14-31. | 0.0 | 1 |
| 387 | Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2022, 22, 299-323. | 1.0 | 16 |
| 388 | The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872. | 1.2 | 5 |
| 389 | Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacologica Sinica, 2022, 43, 2636-2650. | 2.8 | 5 |
| 390 | Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. Minerva Medica, 2022, , . | 0.3 | 2 |
| 391 | Sodiumâ€glucose cotransporterâ€2 inhibitors in heart failure: an updated metaâ€analysis. ESC Heart Failure, 2022, 9, 1942-1953. | 1.4 | 9 |
| 392 | Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. Journal of Cardiovascular Translational Research, 2022, 15, 944-956. | 1.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 393 | Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , . | 0.5 | 2 |
| 394 | Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. Frontiers in Endocrinology, 2022, 13, 850836. | 1.5 | 5 |
| 395 | Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2022, 10, 198-210. | 1.9 | 16 |
| 396 | A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2022, 22, 357-361. | 1.0 | 4 |
| 397 | Heart failure in adults with congenital heart disease. International Journal of Cardiology, 2022, 357, 39-45. | 0.8 | 17 |
| 398 | Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911. | 1.2 | 2 |
| 399 | Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012. | 4.3 | 4 |
| 400 | The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 2022, 11, 1904. | 1.0 | 4 |
| 401 | Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 3587. | 1.8 | 48 |
| 402 | Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert Opinion on Pharmacotherapy, 2022, 23, 673-680. | 0.9 | 3 |
| 403 | Evaluating the Initiation of Sodium/Glucose Cotransporter 2 Inhibitors within 2 Weeks of an Acute Hospital Admission: A Systematic Review and Meta-Analysis of Nine Clinical Trials. Medical Principles and Practice, 2022, 31, 215-223. | 1.1 | 0 |
| 404 | Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318. | 1.9 | 10 |
| 405 | Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure. American Journal of Cardiology, 2022, , . | 0.7 | 0 |
| 406 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063. | 1.6 | 756 |
| 407 | Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50. | 2.7 | 8 |
| 408 | Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288. | 1.6 | 65 |
| 409 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421. | 1.2 | 774 |
| 410 | Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185. | | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 411 | Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. Medical Hypotheses, 2022, 162, 110804. | 0.8 | 0 |
| 412 | Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. Journal of Molecular and Cellular Cardiology, 2022, 167, 17-31. | 0.9 | 52 |
| 413 | Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 157-164. | 0.1 | 0 |
| 414 | Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , . | 1.8 | 0 |
| 415 | Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82. | 1.7 | 6 |
| 416 | Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Advances in Therapy, 2022, 39, 845-861. | 1.3 | 13 |
| 417 | A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030. | 0.7 | 5 |
| 419 | Three new categories of hypoglycaemic agents and various cardiovascular diseases: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 636-642. | 0.7 | 3 |
| 420 | A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393. | 1.4 | 28 |
| 421 | Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Frontiers in Cardiovascular Medicine, 2021, 8, 810791. | 1.1 | 12 |
| 422 | Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression. Current Opinion in Nephrology and Hypertension, 2022, 31, 205-211. | 1.0 | 1 |
| 423 | Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 975-983. | 0.2 | 0 |
| 424 | SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236. | 2.7 | 63 |
| 425 | Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Scoreâ€“matched Population-based Cohort Study. Canadian Journal of Diabetes, 2022, 46, 392-403.e13. | 0.4 | 6 |
| 426 | Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1349-1354. | 0.7 | 6 |
| 428 | Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Journal of Clinical Medicine, 2022, 11, 137. | 1.0 | 15 |
| 429 | Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiology Journal, 2021, 28, 962-969. | 0.5 | 1 |
| 430 | Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400. | 1.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 431 | Diuretics in Treatment of Heart Failure. , 2022, 2, 86-93. | | 0 |
| 432 | Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. , 2022, 2, 55-63. | | 0 |
| 433 | SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. , 2022, 2, 67-71. | | 0 |
| 434 | Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210869. | 1.1 | 12 |
| 435 | Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , . | 1.4 | 2 |
| 436 | Sodiumâ€“Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. Annals of Internal Medicine, 2022, 175, 851-861. | 2.0 | 23 |
| 437 | Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761. | 2.9 | 27 |
| 438 | Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion. Frontiers in Cardiovascular Medicine, 2022, 9, 864366. | 1.1 | 0 |
| 439 | GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114. | 0.6 | 40 |
| 440 | The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43. | 0.0 | 1 |
| 441 | Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naÃ¯ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482. | 2.2 | 0 |
| 442 | Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <scp>REPORTâ€HF</scp> (International Registry to assess <scp>mEdical</scp> Practice with) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Failure, 2022, . . | 2.9 | 12 |
| 443 | Global Benefit of SGLT2 Inhibitors in HeartÂFailure With Reduced EjectionÂFraction. JACC Asia, 2022, 2, 154-156. | 0.5 | 0 |
| 444 | What's all the fuss about a new guideline?. European Journal of Heart Failure, 2022, 24, 743-745. | 2.9 | 0 |
| 445 | Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. Diabetes Research and Clinical Practice, 2022, 187, 109871. | 1.1 | 7 |
| 446 | Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795. | 0.2 | 7 |
| 447 | Kardiologie. , 2022, , 291-388. | | 0 |
| 448 | Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 843-854. | 1.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 449 | Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, . | 1.2 | 1 |
| 450 | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Journal of Molecular Cell Biology, 2022, 14, . | 1.5 | 16 |
| 451 | Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. Current Cardiology Reviews, 2022, 18, . | 0.6 | 1 |
| 452 | FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports, 2022, 12, 7326. | 1.6 | 8 |
| 454 | Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , . | 1.2 | 1 |
| 455 | Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023, 28, 585-596. | 1.7 | 11 |
| 456 | Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062. | 0.7 | 19 |
| 457 | Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports, 2022, 7, 1463-1476. | 0.4 | 59 |
| 458 | Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?. Endocrine Practice, 2022, 28, 795-801. | 1.1 | 5 |
| 459 | The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacological Research, 2022, 180, 106243. | 3.1 | 25 |
| 460 | Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. Nefrologia, 2022, 42, 145-162. | 0.2 | 2 |
| 461 | Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice, 2022, 188, 109927. | 1.1 | 18 |
| 462 | Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular Diabetology, 2022, 21, 74. | 2.7 | 82 |
| 463 | Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926. | 2.9 | 18 |
| 464 | Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068. | 1.2 | 41 |
| 465 | Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98. | 1.2 | 48 |
| 466 | Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. Journal of Nephrology, 2022, , . | 0.9 | 5 |
| 467 | Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938. | 2.2 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 468 | Year in Review 2021: Noteworthy Literature in Cardiothoracic Anesthesia. Seminars in Cardiothoracic and Vascular Anesthesia, 2022, 26, 107-119. | 0.4 | 1 |
| 469 | Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines, 2022, 10, 1168. | 1.4 | 21 |
| 470 | Shortâ€term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (<scp>DAPAâ€VO<sub>2</sub></scp>): a randomized clinical trial. European Journal of Heart Failure, 2022, 24, 1816-1826. | 2.9 | 22 |
| 471 | Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2022, 15, 2186-2199. | 1.4 | 9 |
| 472 | Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Frontiers in Cardiovascular Medicine, 2022, 9, . | 1.1 | 5 |
| 473 | Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2022, 9, . | 1.1 | 9 |
| 474 | Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart, 2022, 9, e001936. | 0.9 | 12 |
| 475 | Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacistâ€™s Perspective. Frontiers in Endocrinology, 2022, 13, . | 1.5 | 2 |
| 476 | Gliflozins in the Management of Cardiovascular Disease. New England Journal of Medicine, 2022, 386, 2024-2034. | 13.9 | 113 |
| 477 | Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. Journal of Clinical Medicine, 2022, 11, 2935. | 1.0 | 4 |
| 478 | Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?. European Medical Journal (Chelmsford,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 337 | 3.0 | 0 |
| 479 | The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review. Cureus, 2022, , . | 0.2 | 1 |
| 480 | Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. American Heart Journal, 2022, 251, 127-136. | 1.2 | 5 |
| 481 | Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Diabetes and Metabolism Journal, 2022, 46, 701-712. | 1.8 | 8 |
| 482 | Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690. | 4.3 | 109 |
| 483 | Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. Journal of Clinical Medicine, 2022, 11, 3192. | 1.0 | 10 |
| 484 | Promise of sodiumâ€“glucose coâ€transporterâ€2 inhibitors in heart failure with mildly reduced ejection fraction. ESC Heart Failure, 0, , . | 1.4 | 2 |
| 485 | Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. Cardiology Plus, 2022, 7, 20-28. | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 486 | Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure. Russian Journal of Cardiology, 2022, 27, 4949. | 0.4 | 3 |
| 487 | Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. Cardiology Journal, 0, , . | 0.5 | 3 |
| 488 | Forecasting HeartÂFailure Risk in Diabetes. Journal of the American College of Cardiology, 2022, 79, 2294-2297. | 1.2 | 2 |
| 489 | Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy, 2022, 39, 3472-3487. | 1.3 | 4 |
| 490 | Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. Diabetes Therapy, 2022, 13, 19-34. | 1.2 | 3 |
| 491 | From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35. | 1.0 | 5 |
| 492 | Clinical Benefits of Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia, 2022, 2, 287-293. | 0.5 | 6 |
| 493 | A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hospital Practice (1995), 0, , . | 0.5 | 0 |
| 494 | New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology, 0, 13, . | 1.6 | 7 |
| 495 | Effects of SGLT2 inhibitors on cardiac structure and function. Heart Failure Reviews, 2023, 28, 697-707. | 1.7 | 5 |
| 496 | Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. Current Heart Failure Reports, 2022, 19, 191-199. | 1.3 | 2 |
| 497 | Implementation of Multiple Evidence-Based Heart Failure Therapies. Current Problems in Cardiology, 2022, , 101293. | 1.1 | 0 |
| 498 | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Frontiers in Endocrinology, 0, 13, . | 1.5 | 6 |
| 499 | From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients. Drugs, 2022, 82, 949-955. | 4.9 | 11 |
| 500 | Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. American Heart Journal Plus, 2022, 18, 100154. | 0.3 | 2 |
| 501 | Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. Canadian Journal of Physiology and Pharmacology, 0, , . | 0.7 | 2 |
| 503 | Side effects and treatment initiation barriers of sodiumâ€“glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632. | 2.9 | 10 |
| 504 | Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Journal of Diabetes Investigation, 2022, 13, 1472-1488. | 1.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Left ventricular ejection fraction as the primary heart failure phenotyping parameter. European Journal of Heart Failure, 2022, 24, 1158-1161. | 2.9 | 15 |
| 506 | Treating Cardiodiabetic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. Cardiometabolic Syndrome Journal, 0, 2, . | 1.0 | 0 |
| 507 | An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations. Diabetes Therapy, 0, , . | 1.2 | 1 |
| 508 | Improving implementation of evidenceâ€based therapies for heart failure. Clinical Cardiology, 2022, 45, . | 0.7 | 2 |
| 509 | Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clinical Cardiology, 2022, 45, . | 0.7 | 8 |
| 511 | In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 0, 8, . | 1.2 | 9 |
| 512 | Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429. | 1.3 | 3 |
| 513 | Clinical Evidence and Proposed Mechanisms of Sodiumâ€“Glucose CotransporterÂ2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?. Cardiac Failure Review, 0, 8, . | 1.2 | 9 |
| 514 | Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. International Journal of Cardiology, 2022, 366, 51-56. | 0.8 | 9 |
| 515 | A surveyâ€based triage tool to identify patients potentially eligible for referral to an advanced heart failure centre. ESC Heart Failure, 2022, 9, 3643-3648. | 1.4 | 3 |
| 516 | Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, . | | 10 |
| 517 | Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction. Clinical Cardiology, 2022, 45, . | 0.7 | 2 |
| 518 | Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis. European Journal of Internal Medicine, 2022, 104, 128-130. | 1.0 | 2 |
| 521 | Los iSGLT2 en la insuficiencia cardiaca. Â¿Sus beneficios pueden extenderse a todo el espectro de la fracciÃ³n de eyecciÃ³n?. Revista Espanola De Cardiologia (English Ed ), 2022, , . | 0.4 | 0 |
| 522 | Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112. | 0.6 | 5 |
| 523 | Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodiumâ€“glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. European Heart Journal Quality of Care & Clinical Outcomes, 0, , . | 1.8 | 2 |
| 524 | Cardiovascular protection by SGLT2 inhibitors â€“ Do anti-inflammatory mechanisms play a role?. Molecular Metabolism, 2022, 64, 101549. | 3.0 | 23 |
| 525 | Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study. Diabetes Care, 2022, 45, 2118-2126. | 4.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 526 | The use of sodium-glucose cotransporter 2 inhibitor in heart failure: The rise of the Roman Empire!. The National Medical Journal of India, 0, 34, 347-350. | 0.1 | 0 |
| 527 | Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. Cardiac Failure Review, 0, 8, . | 1.2 | 2 |
| 528 | Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope. Revista Portuguesa De Cardiologia, 2022, , . | 0.2 | 0 |
| 529 | Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 225. | 0.8 | 3 |
| 530 | The Diabetic Cardiorenal Nexus. International Journal of Molecular Sciences, 2022, 23, 7351. | 1.8 | 6 |
| 532 | Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080. | 2.2 | 16 |
| 533 | Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study. Seminars in Arthritis and Rheumatism, 2022, 56, 152058. | 1.6 | 3 |
| 534 | Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice. Heart Failure Reviews, 0, , . | 1.7 | 4 |
| 535 | Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 381-393. | 1.5 | 7 |
| 536 | Tolerability and safety barriers to sodiumâ€“glucose cotransporter 2 inhibitor initiation in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 1633-1635. | 2.9 | 1 |
| 537 | SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy. Circulation, 2022, 146, 299-302. | 1.6 | 6 |
| 538 | Progress in the management of patients with diabetes and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 456-463. | 1.0 | 1 |
| 539 | Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. Life, 2022, 12, 1112. | 1.1 | 0 |
| 540 | Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia, 2022, 217, 212-217. | 0.8 | 14 |
| 541 | Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. International Journal of Molecular Sciences, 2022, 23, 7966. | 1.8 | 8 |
| 542 | Sodiumâ€glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease. ESC Heart Failure, 0, , . | 1.4 | 1 |
| 543 | Hospital Diabetes Meeting 2022. Journal of Diabetes Science and Technology, 0, , 193229682211108. | 1.3 | 1 |
| 544 | Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?. Expert Opinion on Pharmacotherapy, 2022, 23, 1497-1502. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 545 | Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry. Circulation: Heart Failure, 2022, 15, . | 1.6 | 13 |
| 546 | Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. Current Diabetes Reviews, 2022, 19, . | 0.6 | 1 |
| 547 | 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology, 2022, 38, 1153-1167. | 0.8 | 17 |
| 548 | Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Frontiers in Pharmacology, 0, 13, . | 1.6 | 12 |
| 549 | Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure. Circulation Journal, 2022, 86, 2029-2039. | 0.7 | 4 |
| 551 | Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?. European Heart Journal, 2022, 43, 4754-4757. | 1.0 | 13 |
| 553 | SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction. Cardiovascular Drugs and Therapy, 2023, 37, 989-996. | 1.3 | 7 |
| 554 | American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. Endocrine Practice, 2022, 28, 923-1049. | 1.1 | 146 |
| 555 | Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 18 |
| 556 | Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. Herz, 0, , . | 0.4 | 1 |
| 557 | Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. Journal of Cardiovascular Translational Research, 2023, 16, 327-340. | 1.1 | 4 |
| 558 | Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. International Journal of Molecular Sciences, 2022, 23, 8631. | 1.8 | 7 |
| 559 | Effect of mineralocorticoid receptor antagonist at baseline on the efficacy of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology, 2022, 29, e334-e337. | 0.8 | 2 |
| 560 | SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia, 2022, 65, 2000-2010. | 2.9 | 26 |
| 562 | The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics, 2022, 14, 1730. | 2.0 | 18 |
| 563 | Latent autoimmune diabetes in adults in China. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 564 | Use of sodium glucose coâ€transporter 2 inhibitors in acute heart failure: a practical guidance. ESC Heart Failure, 0, , . | 1.4 | 2 |
| 565 | Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovascular Research, 2023, 118, 3536-3555. | 1.8 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 566 | Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 3 |
| 567 | The Effectiveness of Sodium-Glucose Cotransporter 2ÂInhibitors and Glucagon-like Peptide-1 Receptor AgonistsÂon Cardiorenal Outcomes: Systematic Review andÂMeta-analysis. Canadian Journal of Cardiology, 2022, 38, 1201-1210. | 0.8 | 12 |
| 568 | The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 2583-2597. | 1.1 | 13 |
| 569 | Cardiorenal protection of SGLT2 inhibitorsâ€"Perspectives from metabolic reprogramming. EBioMedicine, 2022, 83, 104215. | 2.7 | 26 |
| 570 | The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. International Immunopharmacology, 2022, 111, 109080. | 1.7 | 28 |
| 571 | Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. IJC Heart and Vasculature, 2022, 42, 101103. | 0.6 | 4 |
| 572 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects. Drug Design, Development and Therapy, 0, Volume 16, 2967-2980. | 2.0 | 2 |
| 573 | Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 19 |
| 574 | SGLT2 Inhibitors Should Be Considered for All Patients With HeartÂFailure. Journal of the American College of Cardiology, 2022, 80, 1311-1313. | 1.2 | 1 |
| 575 | Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 80, 1302-1310. | 1.2 | 49 |
| 576 | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. Methodist DeBakey Cardiovascular Journal, 2022, 18, 62-72. | 0.5 | 3 |
| 577 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial). Journal of the Practice of Cardiovascular Sciences, 2022, 8, 77. | 0.0 | 0 |
| 578 | Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14. | 0.0 | 0 |
| 579 | Overview of trials from AHA 2021. Global Cardiology Science & Practice, 2021, 2021, . | 0.3 | 0 |
| 580 | Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 2022, 28, 1956-1964. | 15.2 | 111 |
| 581 | Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure. European Heart Journal, 2022, 43, 4433-4435. | 1.0 | 2 |
| 582 | Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction. JAMA Cardiology, 2022, 7, 1067. | 3.0 | 12 |
| 583 | Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 584 | Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2022, 11, 5027. | 1.0 | 3 |
| 586 | SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, The, 2022, 400, 757-767. | 6.3 | 307 |
| 587 | Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis. Frontiers in Pharmacology, 0, 13, . | 1.6 | 0 |
| 588 | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 1 |
| 589 | Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65, 1925-1966. | 2.9 | 273 |
| 590 | Impact of Worsening Heart Failure on Long-Term Prognosis in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2022, 184, 63-71. | 0.7 | 2 |
| 591 | New Strategies to Prevent Rehospitalizations for Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 199-212. | 0.4 | 2 |
| 592 | Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. Cardiovascular Research, 2023, 119, 1130-1145. | 1.8 | 6 |
| 593 | â€˜Acute Heart Failureâ€™: Should We Abandon the Term Altogether?. Current Heart Failure Reports, 2022, 19, 425-434. | 1.3 | 3 |
| 594 | Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786. | 4.3 | 435 |
| 595 | HeartÂFailure Drug Treatmentâ€”Inertia,ÂTitration, and Discontinuation. JACC: Heart Failure, 2023, 11, 1-14. | 1.9 | 51 |
| 596 | The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials. Frontiers in Endocrinology, 0, 13, . | 1.5 | 4 |
| 597 | Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. Cureus, 2022, , . | 0.2 | 1 |
| 598 | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 1 |
| 599 | SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 6 |
| 600 | Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, . | | 0 |
| 601 | Incident heart failure, arrhythmias and cardiovascular outcomes with sodiumâ€glucose cotransporter 2 (<scp>SGLT2</scp>) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes, Obesity and Metabolism, 2023, 25, 602-610. | 2.2 | 17 |
| 602 | Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. Journal of Clinical Medicine, 2022, 11, 5199. | 1.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 603 | Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. Pharmaceutics, 2022, 14, 1964. | 2.0 | 0 |
| 604 | Patient preferences for newer oral therapies in type 2 diabetes. International Journal of Cardiology, 2023, 371, 526-532. | 0.8 | 4 |
| 605 | A review of cardiovascular benefits of SGLT2 inhibitors. Medicine (United States), 2022, 101, e30310. | 0.4 | 1 |
| 606 | Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney International Reports, 2022, 7, 2589-2607. | 0.4 | 7 |
| 607 | Cost effectiveness analyses of pharmacological treatments in heart failure. Frontiers in Pharmacology, 0, 13, . | 1.6 | 6 |
| 608 | Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2022, 24, 2387-2389. | 2.9 | 0 |
| 609 | Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Annales D'Endocrinologie, 2023, 84, 57-68. | 0.6 | 2 |
| 610 | A 96â€weekâ€blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism, 2023, 25, 293-301. | 2.2 | 7 |
| 611 | In silicodiscovery of potential sodiumâ€“glucose cotransporter-2 inhibitors from natural products for treatment of heart failure via molecular docking and molecular dynamics simulation approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 8109-8120. | 2.0 | 5 |
| 612 | Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. Heart Failure Clinics, 2022, 18, 645-654. | 1.0 | 3 |
| 613 | SGLT2 Inhibitors in Heart Failure. Heart Failure Clinics, 2022, 18, 587-596. | 1.0 | 6 |
| 614 | Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3442-3451. | 1.8 | 7 |
| 615 | Inhibiting the proximal nephron in acute heart failureÂâ€“Âemerging data on kidney safety and efficacy. European Journal of Heart Failure, 2022, 24, 1853-1855. | 2.9 | 0 |
| 616 | SGLT2 Inhibitors in Type 2 Diabetes Mellitus. Heart Failure Clinics, 2022, 18, 551-559. | 1.0 | 2 |
| 617 | Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success. I P Pavlov Russian Medical Biological Herald, 2022, 30, 411-421. | 0.2 | 1 |
| 618 | SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Heart Failure Clinics, 2022, 18, 561-577. | 1.0 | 2 |
| 619 | Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. Heart Failure Reviews, 2023, 28, 949-959. | 1.7 | 7 |
| 620 | SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 579-586. | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 621 | Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Current Heart Failure Reports, 2022, 19, 467-475. | 1.3 | 2 |
| 622 | SGLT2 Inhibitors Are Lifesavers in Heart Failure. Heart Failure Clinics, 2022, 18, xi-xiv. | 1.0 | 0 |
| 623 | Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 473-489. | 0.9 | 5 |
| 624 | Reporting and Definition of Kidney Death in Heart Failure Clinical Trials. Current Problems in Cardiology, 2022, 47, 101382. | 1.1 | 0 |
| 625 | The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. International Journal of Molecular Sciences, 2022, 23, 11987. | 1.8 | 7 |
| 626 | Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. European Heart Journal, 2023, 44, 41-50. | 1.0 | 63 |
| 627 | Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. Life, 2022, 12, 1663. | 1.1 | 8 |
| 628 | SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines, 2022, 10, 2458. | 1.4 | 9 |
| 629 | Ketones: the double-edged sword of SGLT2 inhibitors?. Diabetologia, 2023, 66, 23-32. | 2.9 | 14 |
| 630 | Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Services Research, 2022, 22, . | 0.9 | 13 |
| 631 | Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 925-936. | 1.7 | 8 |
| 632 | Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 3 |
| 633 | Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. Circulation, 2022, 146, 1507-1517. | 1.6 | 18 |
| 634 | Considerations in the Interpretation of Patient Reported Outcomes in Heart Failure with Reduced and Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, , . | 0.7 | 0 |
| 635 | One size fits all: The story of SGLT2 inhibitors in heart failure. Med, 2022, 3, 735-739. | 2.2 | 3 |
| 636 | Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. European Journal of Heart Failure, 2022, 24, 2029-2036. | 2.9 | 11 |
| 637 | Safety of sodiumâ€“glucose c<scp>otransporter</scp>Â2 inhibitors in Asian typeâ€‰2 diabetes populations. Journal of Diabetes Investigation, 2023, 14, 167-182. | 1.1 | 3 |
| 638 | A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications, 2022, 13, . | 5.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 639 | SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology, 2022, 936, 175354. | 1.7 | 4 |
| 640 | Emerging roles of sodiumâ€glucose coâ€transporter inhibitors. The Prescriber, 2022, 33, 11-17. | 0.1 | 0 |
| 641 | Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 186, 150-155. | 0.7 | 5 |
| 642 | Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial. Journal of Cardiac Failure, 2023, 29, 33-41. | 0.7 | 8 |
| 643 | Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. Structural Heart, 2022, , 100082. | 0.2 | 0 |
| 644 | KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2022, 102, S1-S127. | 2.6 | 246 |
| 645 | Cardiorenal disease management in type 2 diabetes: An expert consensus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102661. | 1.8 | 1 |
| 646 | Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 0 |
| 647 | Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1957-1974. | 0.9 | 0 |
| 648 | Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney International, 2022, 102, 990-999. | 2.6 | 78 |
| 649 | Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction. European Journal of Pharmacology, 2022, 936, 175357. | 1.7 | 6 |
| 650 | Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care, 2022, 7, 216-224. | 0.1 | 0 |
| 651 | Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 869-881. | 5.5 | 15 |
| 652 | Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet, The, 2022, 400, 1938-1952. | 6.3 | 226 |
| 653 | Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 4 |
| 654 | The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life, 2022, 12, 1829. | 1.1 | 9 |
| 655 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, The, 2022, 400, 1788-1801. | 6.3 | 249 |
| 656 | Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges. European Heart Journal, 0, , . | 1.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 657 | Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovascular Diabetology, 2022, 21, . | 2.7 | 3 |
| 658 | Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Frontiers in Physiology, 0, 13, . | 1.3 | 1 |
| 659 | Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2022, 15, . | 1.6 | 10 |
| 660 | Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Failure, 2023, 10, 776-790. | 1.4 | 6 |
| 661 | Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice, 2022, 194, 110161. | 1.1 | 11 |
| 662 | Risk of hypovolemia associated with sodiumâ€“glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 4 |
| 663 | Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. European Heart Journal Supplements, 2022, 24, I153-I159. | 0.0 | 1 |
| 664 | Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. BMJ Open Diabetes Research and Care, 2022, 10, e002995. | 1.2 | 6 |
| 665 | Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation, 2023, 147, 284-295. | 1.6 | 13 |
| 666 | Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications, 2022, 36, 108352. | 1.2 | 3 |
| 667 | <scp>Healthâ€related</scp> quality of life outcomes in <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 2264-2274. | 2.9 | 6 |
| 669 | Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. American Journal of Cardiology, 2023, 187, 93-99. | 0.7 | 2 |
| 670 | Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53. | 0.5 | 0 |
| 671 | Lessons from the EMPEROR Preserved. , 2022, 2, 329-330. | | 0 |
| 672 | Corrigendum to â€œMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ€• [Biochem. Pharmacol. 206 (2022) 115304]. Biochemical Pharmacology, 2023, 207, 115349. | 2.0 | 0 |
| 673 | The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46. | | 9 |
| 674 | Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodiumâ€“Glucose Co-transporter-2 Inhibitors. European Endocrinology, 2022, 18, 106. | 0.8 | 4 |
| 675 | Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?. Cureus, 2022, , . | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 676 | Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Frontiers in Pharmacology, 0, 13, . | 1.6 | 1 |
| 677 | Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 925-937. | 2.0 | 2 |
| 678 | The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. Pharmacy (Basel, Switzerland), 2022, 10, 166. | 0.6 | 2 |
| 679 | Diabetes mellitus type 1 and coronary artery disease with severe systolic heart failure in 25 year-old adult. Diabetes Mellitus, 2022, 25, 514-521. | 0.5 | 0 |
| 680 | Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023, 19, 151-163. | 4.3 | 21 |
| 681 | Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World Journal of Cardiology, 0, 14, 599-616. | 0.5 | 1 |
| 682 | Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?. European Heart Journal, 2023, 44, 51-53. | 1.0 | 6 |
| 683 | The EMPULSE Trial. Intervencni A Akutni Kardiologie, 2022, 21, 174-177. | 0.0 | 0 |
| 684 | Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. International Journal of Cardiology, 2022, , . | 0.8 | 1 |
| 685 | SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Healthcare (Switzerland), 2022, 10, 2356. | 1.0 | 1 |
| 686 | Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. JAMA Network Open, 2022, 5, e2243201. | 2.8 | 6 |
| 687 | Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 3 |
| 688 | Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481. | 1.8 | 4 |
| 689 | Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. American Journal of Cardiovascular Drugs, 2023, 23, 113-126. | 1.0 | 2 |
| 690 | Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 1 |
| 691 | Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics, 2022, 13, 115-123. | 0.2 | 0 |
| 692 | Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial. American Heart Journal, 2023, 257, 85-92. | 1.2 | 1 |
| 693 | The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. Expert Review of Cardiovascular Therapy, 2023, 21, 15-34. | 0.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 694 | 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S158-S190. | 4.3 | 156 |
| 695 | Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society, 2022, 7, . | 0.1 | 2 |
| 697 | Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. American Journal of Medicine, 2023, 136, 260-269.e7. | 0.6 | 10 |
| 698 | Cardiovascular Alterations and Structural Changes in the Setting of Chronic Kidney Disease: a Review of Cardiorenal Syndrome Type 4. SN Comprehensive Clinical Medicine, 2023, 5, . | 0.3 | 2 |
| 699 | Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist. Cardiac Failure Review, 0, 8, . | 1.2 | 1 |
| 700 | The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice. Cardiology, 2023, 148, 27-37. | 0.6 | 3 |
| 701 | Getting ahead of the game: in-hospital initiation of HFrEF therapies. European Heart Journal Supplements, 2022, 24, L38-L44. | 0.0 | 3 |
| 702 | Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Frontiers in Endocrinology, 0, 13, . | 1.5 | 3 |
| 703 | The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest. Life, 2022, 12, 2062. | 1.1 | 5 |
| 704 | Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. , 2023, 242, 108330. | | 5 |
| 706 | Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ESC Heart Failure, 2023, 10, 1555-1569. | 1.4 | 3 |
| 707 | The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19. | 0.0 | 6 |
| 708 | Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. European Heart Journal Supplements, 2022, 24, L20-L28. | 0.0 | 7 |
| 709 | New Insights into the Use of Empagliflozinâ€”A Comprehensive Review. Biomedicines, 2022, 10, 3294. | 1.4 | 6 |
| 710 | Targeting the â€˜vulnerableâ€™ periodÂâ€“Âfirst 3â€“6Âmonths after an acute heart failure admissionÂâ€“Âthe light gets brighter. European Journal of Heart Failure, 2023, 25, 30-34. | 2.9 | 5 |
| 711 | Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?. Revista Romana De Cardiologie, 2022, 32, 167-173. | 0.0 | 1 |
| 712 | New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. Updates in Hypertension and Cardiovascular Protection, 2023, , 337-349. | 0.1 | 0 |
| 713 | Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute HeartÂFailureÂHospitalization. JACC: Heart Failure, 2023, 11, 596-606. | 1.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 714 | Costâ€effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 0, , . | 2.9 | 3 |
| 715 | Use of <scp>patientâ€reported</scp> outcomes in heart failure: from clinical trials to routine practice. European Journal of Heart Failure, 2023, 25, 139-151. | 2.9 | 16 |
| 716 | Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vascular Medicine, 2023, 28, 62-76. | 0.8 | 4 |
| 717 | Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine, 2023, 176, 381-387. | 2.0 | 35 |
| 718 | SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nature Reviews Cardiology, 2023, 20, 443-462. | 6.1 | 38 |
| 719 | Acute heart failure after nonâ€cardiac surgery: incidence, phenotypes, determinants and outcomes. European Journal of Heart Failure, 2023, 25, 347-357. | 2.9 | 7 |
| 720 | Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. Kidney and Dialysis, 2023, 3, 56-72. | 0.5 | 3 |
| 721 | Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. Journal of Cardiovascular Pharmacology, 2023, 81, 4-14. | 0.8 | 11 |
| 722 | Albuminuria and HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 270-282. | 1.2 | 15 |
| 723 | Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clinical Research in Cardiology, 2023, 112, 1044-1055. | 1.5 | 5 |
| 724 | Little at a time: trying to understand the battery of benefits of sodiumâ€“glucose contransporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2023, 25, 235-237. | 2.9 | 2 |
| 725 | Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. Drugs in Context, 0, 12, 1-14. | 1.0 | 1 |
| 726 | Control of Blood Glucose and Cardiovascular Risk Profile. Updates in Hypertension and Cardiovascular Protection, 2023, , 451-469. | 0.1 | 0 |
| 727 | Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapyâ€"A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. Journal of Clinical Medicine, 2023, 12, 379. | 1.0 | 4 |
| 728 | Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. Diabetes and Metabolism, 2023, 49, 101419. | 1.4 | 9 |
| 729 | Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. European Journal of Medical Research, 2022, 27, . | 0.9 | 6 |
| 730 | Consider this SGLT2 inhibitor for patients with HF with preserved ejection fraction. , 2022, 71, . | | 0 |
| 731 | Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Medicine (United States), 2022, 101, e32489. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 732 | Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. Cardiology in Review, 2024, 32, 114-123. | 0.6 | 4 |
| 733 | Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, . | 1.1 | 11 |
| 734 | Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. ESC Heart Failure, 2023, 10, 1231-1241. | 1.4 | 5 |
| 735 | SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines, 2023, 11, 279. | 1.4 | 7 |
| 736 | Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Frontiers in Endocrinology, 0, 14, . | 1.5 | 6 |
| 737 | Impact of baseline kidney function on the effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors on kidney and heart failure outcomes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 1341-1350. | 2.2 | 7 |
| 738 | Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Canadian Journal of Kidney Health and Disease, 2023, 10, 205435812211505. | 0.6 | 3 |
| 739 | Management of Heart Failure With Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101596. | 1.1 | 5 |
| 740 | Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 343-352. | 1.4 | 2 |
| 741 | Use of sodiumâ€“glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation. CMAJ Open, 2023, 11, E101-E109. | 1.1 | 3 |
| 742 | Worsening HeartÂFailure: Nomenclature, Epidemiology, and Future Directions. Journal of the American College of Cardiology, 2023, 81, 413-424. | 1.2 | 50 |
| 743 | Kidney Drug Transporters in Pharmacotherapy. International Journal of Molecular Sciences, 2023, 24, 2856. | 1.8 | 5 |
| 744 | Sodium-Glucose Cotransporter-2ÂInhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology, 2023, 48, 101597. | 1.1 | 4 |
| 745 | Research Progress of SGLT2 Inhibitors in the Treatment of Heart Failure Complicated with Atrial Fibrillation. Advances in Clinical Medicine, 2023, 13, 2632-2642. | 0.0 | 0 |
| 746 | Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes and Endocrinology,the, 2023, 11, 233-241. | 5.5 | 8 |
| 747 | Time to Benefit With Sotagliflozin in Patients With Worsening HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 1546-1549. | 1.2 | 4 |
| 748 | Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12â€week, multicentre, randomized, doubleâ€blind, placeboâ€controlled, phase 2 trial. Diabetes, Obesity and Metabolism, 2023, 25, 2096-2104. | 2.2 | 4 |
| 749 | Regional management of worsening heart failure: rationale and design of the CHAINâ€HF registry. ESC Heart Failure, 2023, 10, 2074-2083. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 750 | Potential global impact of <scp>sodiumâ€“glucose</scp> cotransporterâ€2 inhibitors in heart failure. European Journal of Heart Failure, 2023, 25, 999-1009. | 2.9 | 9 |
| 751 | Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology, 2023, 16, 149-160. | 1.3 | 5 |
| 752 | Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis. American Heart Journal Plus, 2023, 26, 100261. | 0.3 | 7 |
| 753 | Medication-Attributable Adverse EventsÂin HeartÂFailure Trials. JACC: Heart Failure, 2023, 11, 425-436. | 1.9 | 1 |
| 754 | Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?. Archives of Medical Science, 2023, 19, 528-531. | 0.4 | 0 |
| 755 | Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2023, , . | 0.6 | 0 |
| 756 | Letter by Sawami et al Regarding Article, â€œEffects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)â€• Circulation, 2023, 147, . | 1.6 | 1 |
| 757 | Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, . | 1.1 | 2 |
| 758 | Pharmacotherapy treatment patterns at hospital discharge and clinical outcomes among patients with heart failure with reduced ejection fraction. Chronic Diseases and Translational Medicine, 2023, 9, 154-163. | 0.9 | 0 |
| 759 | Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. Life, 2023, 13, 497. | 1.1 | 5 |
| 760 | Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium. Cardiovascular Drugs and Therapy, 0, , . | 1.3 | 3 |
| 761 | Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes, Obesity and Metabolism, 2023, 25, 1646-1657. | 2.2 | 10 |
| 762 | Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. Cureus, 2023, , . | 0.2 | 1 |
| 763 | Evaluation of heart failure admission as a surrogate for mortality in randomized clinical trials: A metaâ€analysis. European Journal of Clinical Investigation, 2023, 53, . | 1.7 | 2 |
| 764 | SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina (Lithuania), 2023, 59, 388. | 0.8 | 4 |
| 765 | The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy, 2023, 45, 547-555. | 1.0 | 3 |
| 766 | Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Annals of Pharmacotherapy, 2023, 57, 1291-1301. | 0.9 | 1 |
| 767 | The renaissance of one-dimensional carbon nanotubes in tissue engineering. Nano Today, 2023, 49, 101784. | 6.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 768 | Recency of HeartÂFailure Hospitalization, Outcomes, and the Effect of Empagliflozin. JACC: Heart Failure, 2023, 11, 702-712. | 1.9 | 1 |
| 769 | The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. Current Pharmaceutical Design, 2023, 29, 481-493. | 0.9 | 1 |
| 770 | Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Clinical and Laboratory Variables in Heart Failure Patients with Reduced Left Ventricular Ejection Fraction in a Latin American Hospital: A Retrospective Study. Hearts, 2023, 4, 20-27. | 0.4 | 0 |
| 771 | Sacubitrilâ€“valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis. Frontiers in Pharmacology, 0, 14, . | 1.6 | 0 |
| 772 | SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. Journal of Internal Medicine, 2023, 293, 550-558. | 2.7 | 0 |
| 773 | Sotagliflozin, a dual sodiumâ€glucose coâ€transporterâ€1 and sodiumâ€glucose coâ€transporterâ€2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno <scp>T1</scp> Risk Engine in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 1874-1882. | 2.2 | 4 |
| 774 | Proposed New Conceptualization for Definition of DecompensatedÂHF. JACC: Heart Failure, 2023, 11, 368-371. | 1.9 | 2 |
| 775 | Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 2023, 147, 1067-1078. | 1.6 | 3 |
| 776 | Acute Cardiorenal Syndrome: An Update. Cardiology in Review, 0, Publish Ahead of Print, . | 0.6 | 0 |
| 777 | Identifying the patient with heart failure to be treated with vericiguat. Current Medical Research and Opinion, 2023, 39, 661-669. | 0.9 | 1 |
| 778 | Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114. | 0.8 | 0 |
| 779 | SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart Journal, 2023, 75, 122-127. | 0.2 | 9 |
| 780 | Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure. Biomedicines, 2023, 11, 876. | 1.4 | 1 |
| 781 | Regulated cell death pathways in cardiomyopathy. Acta Pharmacologica Sinica, 2023, 44, 1521-1535. | 2.8 | 12 |
| 782 | Early Initiation of Dapagliflozin during Hospitalization for Acute Heart Failure is Associated with a Shorter Hospital Stay. Internal Medicine, 2023, , . | 0.3 | 0 |
| 783 | Efficacy of sodiumâ€“glucose cotransporter 2 inhibitors and angiotensin <scp>receptorâ€“neprilysin</scp> inhibitors for heart failure in black patients: a systematic review and <scp>metaâ€analysis</scp> of randomized controlled trials. European Journal of Heart Failure, 2023, 25, 591-593. | 2.9 | 0 |
| 784 | Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction. Journal of Clinical Medicine, 2023, 12, 2410. | 1.0 | 2 |
| 785 | SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. International Journal of Heart Failure, 2023, 5, 82. | 0.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 786 | SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Metaâ€analysis of randomized clinical trials. Journal of Cardiovascular Electrophysiology, 2023, 34, 1277-1285. | 0.8 | 14 |
| 787 | Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization. Expert Opinion on Pharmacotherapy, 2023, 24, 705-713. | 0.9 | 0 |
| 788 | Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review. American Journal of Health-System Pharmacy, 0, , . | 0.5 | 0 |
| 789 | Systematic review of sodiumâ€glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failureâ€related events. ESC Heart Failure, 2023, 10, 1499-1530. | 1.4 | 8 |
| 790 | Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. Clinical Drug Investigation, 2023, 43, 241-250. | 1.1 | 0 |
| 791 | The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 858-868. | 2.2 | 0 |
| 792 | Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. , 2023, , 337-363. | | 0 |
| 793 | Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. JACC: Heart Failure, 2023, 11, 422-424. | 1.9 | 0 |
| 794 | Evolving Diagnostic and Management Advances in Coronary Heart Disease. Life, 2023, 13, 951. | 1.1 | 3 |
| 795 | Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Critical Care Medicine, 2023, 51, 1074-1085. | 0.4 | 2 |
| 796 | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review. Cureus, 2023, , . | 0.2 | 0 |
| 797 | Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine, 2023, 12, 2824. | 1.0 | 1 |
| 798 | A review of current key guidelines for managing highâ€risk patients with diabetes and heart failure and future prospects. Diabetes, Obesity and Metabolism, 2023, 25, 33-47. | 2.2 | 0 |
| 799 | Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Cardiosomatics, 2023, 13, 198-205. | 0.2 | 0 |
| 800 | Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins. Current Hypertension Reports, 2023, 25, 91-106. | 1.5 | 2 |
| 801 | CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. WiadomoÅ›ci Lekarskie, 2023, 76, 645-650. | 0.1 | 0 |
| 802 | Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients With Acute Decompensated Heart Failure. Circulation Reports, 2023, , . | 0.4 | 0 |
| 803 | Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. Life, 2023, 13, 1024. | 1.1 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 804 | Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842311622. | 1.0 | 0 |
| 805 | Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2023, 24, 935-945. | 0.9 | 1 |
| 806 | The Role of SGLT2 Inhibitors in Cardiovascular Management. Cardiology in Review, 0, Publish Ahead of Print, . | 0.6 | 0 |
| 807 | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art. Iberoamerican Journal of Medicine, 2023, 5, 68-77. | 0.1 | 1 |
| 808 | Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation, 2023, 147, 1654-1669. | 1.6 | 15 |
| 809 | 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2023, 81, 1835-1878. | 1.2 | 74 |
| 810 | Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide. Current Cardiology Reports, 0, , . | 1.3 | 0 |
| 811 | Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation. Kardiologiya, 2023, 63, 66-76. | 0.3 | 1 |
| 837 | Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes. Cardiovascular Drugs and Therapy, 0, , . | 1.3 | 6 |
| 860 | Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nature Reviews Cardiology, 2023, 20, 812-829. | 6.1 | 14 |
| 863 | Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070. | 0.0 | 0 |
| 864 | Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781. | 0.0 | 0 |
| 866 | Systematic Review of the Economic Evaluation of Sodiumâ€“Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. Clinical Drug Investigation, 2023, 43, 463-474. | 1.1 | 0 |
| 879 | Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?. , 2023, 2, 705-707. | | 3 |
| 895 | Kidney Considerations in Pediatric Obesity. Current Obesity Reports, 2023, 12, 332-344. | 3.5 | 2 |
| 899 | Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs, 0, , . | 1.0 | 0 |
| 906 | Myocardial Metabolic Reprogramming in HFpEF. Journal of Cardiovascular Translational Research, 2024, 17, 121-132. | 1.1 | 1 |
| 916 | Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437. | 15.2 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 946 | Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection. Cardiovascular Drugs and Therapy, 0, , . | 1.3 | 1 |
| 987 | Natriuretic peptide testing strategies in heart failure: A 2023 update. Advances in Clinical Chemistry, 2023, , . | 1.8 | 0 |
| 1015 | Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218. | 0.0 | 0 |
| 1031 | Use of Non-insulin Agents for Hyperglycemia Management in Hospitalized Patients. Contemporary Endocrinology, 2023, , 77-91. | 0.3 | 0 |
| 1032 | Glycemic Management in Coronary Artery Bypass Graft Patients. Contemporary Endocrinology, 2023, , 307-322. | 0.3 | 0 |
| 1076 | Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions. , 2024, , 401-416. | | 0 |